<p>Aveanna Healthcare（納斯達克代碼：AVAH - 獲取免費報告）於週四公佈了其財報。公司報告本季度每股收益為 0.18 美元，超出分析師一致預期的 0.13 美元，超出幅度為 0.05 美元，FiscalAI 報道。該公司本季度的收入為 6.4792 億美元，而分析師預期為 6.1322 億美元。Aveanna Healthcare 的股本回報率為 481.69%，淨利潤率為 9.25%。該公司的季度收入同比增長 15.9%。</p>
<p>獲取 <strong>Aveanna Healthcare</strong> 的提醒：</p>
<p>以下是 Aveanna Healthcare 電話會議的關鍵要點：</p>
<ul>
<li><strong>Aveanna 發佈了強勁的第一季度業績</strong>，收入約為 6.48 億美元，同比增長 15.9%，調整後的息税折舊攤銷前利潤（EBITDA）為 8440 萬美元，同比增長 25.2%，得益於更好的費率、更高的交易量和運營效率。</li>
<li><strong>公司提高了 2026 財年的指引</strong>，預計收入為 25.6 億至 25.8 億美元，調整後的 EBITDA 為 3.28 億至 3.32 億美元，不包括待完成的 Family First 收購。</li>
<li><strong>優先支付者戰略在所有業務中持續獲得 traction</strong>，第一季度新增 4 個 PDS 優先支付者協議、4 個家庭健康協議和 2 個醫療解決方案協議。</li>
<li><strong>管理層表示新的 CMS 家庭健康暫停不會影響 Aveanna</strong> 或其 Family First 收購，並且不會改變公司的 2026 年或 2027 年的商業計劃。</li>
<li><strong>資產負債表和現金生成保持穩健</strong>，流動性約為 5.25 億美元，淨槓桿率為 3.8 倍，管理層重申了進一步去槓桿化的路徑，並計劃進行小規模收購。</li>
</ul>
<h2>Aveanna Healthcare 股價上漲 9.9%</h2>
<p>週四，AVAH 股票上漲 0.67 美元，達到 7.44 美元。該公司交易了 4,276,480 股股票，而其平均交易量為 1,274,675 股。Aveanna Healthcare 的 52 周低點為 3.73 美元，52 周高點為 10.32 美元。公司的流動比率為 1.32，速動比率為 1.32，債務與股本比率為 6.62。該公司的市值為 16.2 億美元，市盈率為 7.29，貝塔值為 1.93。公司的 50 日簡單移動平均線為 6.70 美元，200 日簡單移動平均線為 7.94 美元。</p>
<h2>內部交易活動</h2>
<p>在相關消息中，首席財務官 Matthew Buckhalter 於 2 月 19 日（星期四）出售了 13,512 股公司的股票，交易價格為每股 7.21 美元，總交易額為 97,421.52 美元。出售完成後，首席財務官直接持有公司股票 529,243 股，價值約為 3,815,842.03 美元。此次交易代表其持股減少了 2.49%。該交易已在與證券交易委員會的法律文件中披露，相關信息可通過 SEC 網站獲取。此外，內部人士 Patrick A. Cunningham 於 2 月 19 日（星期四）出售了 18,436 股公司的股票，交易價格為每股 7.21 美元，總價值為 132,923.56 美元。出售後，該內部人士直接持有公司股票 337,755 股，價值為 2,435,213.55 美元。這代表其持股減少了 5.18%。該交易的披露信息可在 SEC 文件中找到。內部人士在過去三個月內出售了價值 5,458,175 美元的 738,957 股公司股票。公司內部人士持有公司股票的 5.30%。</p>
<h2>機構投資者對 Aveanna Healthcare 的看法</h2>
<p>機構投資者和對沖基金最近買賣了該公司的股票。Quantbot Technologies LP 在第二季度購買了 Aveanna Healthcare 的新股份，價值 43,000 美元。Oxford Asset Management LLP 在第二季度購買了 Aveanna Healthcare 的新股份，價值 64,000 美元。Bayesian Capital Management LP 在第二季度購買了 Aveanna Healthcare 的新股份，價值 85,000 美元。Jain Global LLC 在第四季度購買了 Aveanna Healthcare 的新股份，價值 102,000 美元。最後，Invesco Ltd.在第二季度將其在 Aveanna Healthcare 的持股增加了 31.1%。Invesco Ltd.現在擁有 20,006 股公司股票，價值 105,000 美元，此前在上個季度又購買了 4,742 股。87.96% 的股票由機構投資者持有。</p>
<h2>分析師設定新的目標價</h2>
<p>AVAH 最近成為多份研究報告的主題。Raymond James Financial 將 Aveanna Healthcare 的評級從 “跑贏大盤” 上調至 “強力買入”，並在 3 月 20 日的報告中設定了 13.00 美元的目標價。Truist Financial 將 Aveanna Healthcare 的目標價從 9.00 美元下調至 8.00 美元，並在 4 月 13 日的報告中為該公司設定了 “持有” 評級。Zacks Research 在 2 月 3 日的報告中將 Aveanna Healthcare 的評級從 “強力買入” 下調至 “持有”。BMO Capital Markets 在 3 月 20 日的報告中將 Aveanna Healthcare 的目標價從 11.00 美元下調至 10.00 美元，併為該公司設定了 “跑贏大盤” 評級。最後，Barclays 在 3 月 25 日的報告中將 Aveanna Healthcare 的目標價從 11.00 美元下調至 9.50 美元，併為該公司設定了 “增持” 評級。一位投資分析師對該股票給予了強力買入評級，四位給予了買入評級，六位給予了持有評級。根據 MarketBeat，該股票目前的共識評級為 “適度買入”，共識目標價為 10.25 美元。</p>
<p><strong>查看我們關於 AVAH 的最新報告</strong></p>
<h2>關於 Aveanna Healthcare</h2>
<p>（獲取免費報告）</p>
<p>Aveanna Healthcare, Inc NASDAQ: AVAH 是一家全國性的居家醫療服務提供商，專注於為醫學複雜和慢性病兒童提供兒科專業護理、治療及相關支持。該公司提供一系列臨牀和治療解決方案，旨在使患者能夠在自己舒適的家中接受護理，從而減少住院和長期機構護理的需求。Aveanna 的服務包括註冊護士、物理治療、職業治療、語言治療、行為健康諮詢以及耐用醫療設備協調。</p>
<p>除了兒科居家健康服務外，Aveanna 還運營成人居家健康和個人護理支持項目，幫助老年人和殘疾成年人進行日常生活活動、藥物管理和康復治療。</p>
<h2>推薦故事</h2>
<ul>
<li>五隻我們認為比 Aveanna Healthcare 更好的股票</li>
<li>YETI 在財報超預期和上調前景後反彈</li>
<li>三家領先量子公司的 Q1 財報對比</li>
<li>思科的垂直反彈可能仍處於早期階段</li>
<li>亞馬遜與阿里巴巴：現在顯然更具價值的選擇</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVZBSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVZBSA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Aveanna Healthcare 嗎？</h2>
<p>在考慮 Aveanna Healthcare 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Aveanna Healthcare 並不在名單上。</p>
<p>儘管 Aveanna Healthcare 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

AVAH

<p>Aveanna Healthcare（納斯達克代碼：AVAH）報告了第一季度每股收益為 0.18 美元，超出預期 0.05 美元。收入達到 6.4792 億美元，同比增長 15.9%，超過預期的 6.1322 億美元。該公司將 2026 年的收入指引上調至 25.6 億至 25.8 億美元。公告發布後，股價上漲 9.9%，至 7.44 美元。首席財務官和另一位內部人士出售了股份，而機構持股比例為 87.96%。分析師設定了新的目標價為 13.00 美元，反映出對公司業績和前景的積極情緒</p>

<p>Aveanna Healthcare (NASDAQ:AVAH - Get Free Report) announced its earnings results on Thursday. The company reported $0.18 EPS for the quarter, topping analysts' consensus estimates of $0.13 by $0.05, FiscalAI reports. The firm had revenue of $647.92 million during the quarter, compared to analysts' expectations of $613.22 million. Aveanna Healthcare had a return on equity of 481.69% and a net margin of 9.25%.The business's revenue for the quarter was up 15.9% on a year-over-year basis.</p>
<div class="lb-trans"><p>Aveanna Healthcare（納斯達克代碼：AVAH - 獲取免費報告）於週四公佈了其財報。公司報告本季度每股收益為 0.18 美元，超出分析師一致預期的 0.13 美元，超出幅度為 0.05 美元，FiscalAI 報道。該公司本季度的收入為 6.4792 億美元，而分析師預期為 6.1322 億美元。Aveanna Healthcare 的股本回報率為 481.69%，淨利潤率為 9.25%。該公司的季度收入同比增長 15.9%。</p>
</div><p>Get <strong>Aveanna Healthcare</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Aveanna Healthcare</strong> 的提醒：</p>
</div><p>Here are the key takeaways from Aveanna Healthcare's conference call:</p>
<div class="lb-trans"><p>以下是 Aveanna Healthcare 電話會議的關鍵要點：</p>
</div><ul>
<li><strong>Aveanna posted strong Q1 results</strong> with revenue of about $648 million, up 15.9% year over year, and adjusted EBITDA of $84.4 million, up 25.2%, driven by better rates, higher volumes, and operational efficiencies.</li>
<li><strong>The company raised full-year 2026 guidance</strong> to revenue of $2.56 billion-$2.58 billion and adjusted EBITDA of $328 million-$332 million, excluding the pending Family First acquisition.</li>
<li><strong>Preferred payer strategy continues to gain traction</strong> across all businesses, with 4 new PDS preferred payer agreements, 4 new Home Health agreements, and 2 new Medical Solutions agreements in Q1.</li>
<li><strong>Management said the new CMS Home Health moratorium should not affect Aveanna</strong> or its Family First acquisition, and it does not change the company’s 2026 or 2027 business plans.</li>
<li><strong>Balance sheet and cash generation remain solid</strong>, with liquidity of about $525 million and net leverage at 3.8x, while management reiterated a path toward further deleveraging alongside tuck-in acquisitions.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>Aveanna 發佈了強勁的第一季度業績</strong>，收入約為 6.48 億美元，同比增長 15.9%，調整後的息税折舊攤銷前利潤（EBITDA）為 8440 萬美元，同比增長 25.2%，得益於更好的費率、更高的交易量和運營效率。</li>
<li><strong>公司提高了 2026 財年的指引</strong>，預計收入為 25.6 億至 25.8 億美元，調整後的 EBITDA 為 3.28 億至 3.32 億美元，不包括待完成的 Family First 收購。</li>
<li><strong>優先支付者戰略在所有業務中持續獲得 traction</strong>，第一季度新增 4 個 PDS 優先支付者協議、4 個家庭健康協議和 2 個醫療解決方案協議。</li>
<li><strong>管理層表示新的 CMS 家庭健康暫停不會影響 Aveanna</strong> 或其 Family First 收購，並且不會改變公司的 2026 年或 2027 年的商業計劃。</li>
<li><strong>資產負債表和現金生成保持穩健</strong>，流動性約為 5.25 億美元，淨槓桿率為 3.8 倍，管理層重申了進一步去槓桿化的路徑，並計劃進行小規模收購。</li>
</ul>
</div><h2>Aveanna Healthcare Trading Up 9.9%</h2>
<div class="lb-trans"><h2>Aveanna Healthcare 股價上漲 9.9%</h2>
</div><p>Shares of AVAH stock traded up $0.67 on Thursday, reaching $7.44. 4,276,480 shares of the company's stock were exchanged, compared to its average volume of 1,274,675. Aveanna Healthcare has a 52 week low of $3.73 and a 52 week high of $10.32. The company has a current ratio of 1.32, a quick ratio of 1.32 and a debt-to-equity ratio of 6.62. The stock has a market capitalization of $1.62 billion, a PE ratio of 7.29 and a beta of 1.93. The company's fifty day simple moving average is $6.70 and its 200 day simple moving average is $7.94.</p>
<div class="lb-trans"><p>週四，AVAH 股票上漲 0.67 美元，達到 7.44 美元。該公司交易了 4,276,480 股股票，而其平均交易量為 1,274,675 股。Aveanna Healthcare 的 52 周低點為 3.73 美元，52 周高點為 10.32 美元。公司的流動比率為 1.32，速動比率為 1.32，債務與股本比率為 6.62。該公司的市值為 16.2 億美元，市盈率為 7.29，貝塔值為 1.93。公司的 50 日簡單移動平均線為 6.70 美元，200 日簡單移動平均線為 7.94 美元。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部交易活動</h2>
</div><p>In related news, CFO Matthew Buckhalter sold 13,512 shares of the firm's stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $7.21, for a total transaction of $97,421.52. Following the completion of the sale, the chief financial officer directly owned 529,243 shares of the company's stock, valued at approximately $3,815,842.03. This trade represents a 2.49% decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, insider Patrick A. Cunningham sold 18,436 shares of the firm's stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $7.21, for a total value of $132,923.56. Following the sale, the insider directly owned 337,755 shares of the company's stock, valued at $2,435,213.55. This represents a 5.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 738,957 shares of company stock worth $5,458,175 in the last three months. Corporate insiders own 5.30% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，首席財務官 Matthew Buckhalter 於 2 月 19 日（星期四）出售了 13,512 股公司的股票，交易價格為每股 7.21 美元，總交易額為 97,421.52 美元。出售完成後，首席財務官直接持有公司股票 529,243 股，價值約為 3,815,842.03 美元。此次交易代表其持股減少了 2.49%。該交易已在與證券交易委員會的法律文件中披露，相關信息可通過 SEC 網站獲取。此外，內部人士 Patrick A. Cunningham 於 2 月 19 日（星期四）出售了 18,436 股公司的股票，交易價格為每股 7.21 美元，總價值為 132,923.56 美元。出售後，該內部人士直接持有公司股票 337,755 股，價值為 2,435,213.55 美元。這代表其持股減少了 5.18%。該交易的披露信息可在 SEC 文件中找到。內部人士在過去三個月內出售了價值 5,458,175 美元的 738,957 股公司股票。公司內部人士持有公司股票的 5.30%。</p>
</div><h2>Institutional Investors Weigh In On Aveanna Healthcare</h2>
<div class="lb-trans"><h2>機構投資者對 Aveanna Healthcare 的看法</h2>
</div><p>Institutional investors and hedge funds have recently bought and sold shares of the company. Quantbot Technologies LP bought a new stake in Aveanna Healthcare during the 2nd quarter valued at $43,000. Oxford Asset Management LLP bought a new stake in Aveanna Healthcare during the 2nd quarter valued at $64,000. Bayesian Capital Management LP bought a new stake in Aveanna Healthcare during the 2nd quarter valued at $85,000. Jain Global LLC bought a new stake in Aveanna Healthcare during the 4th quarter valued at $102,000. Finally, Invesco Ltd. raised its position in Aveanna Healthcare by 31.1% during the 2nd quarter. Invesco Ltd. now owns 20,006 shares of the company's stock valued at $105,000 after purchasing an additional 4,742 shares in the last quarter. 87.96% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>機構投資者和對沖基金最近買賣了該公司的股票。Quantbot Technologies LP 在第二季度購買了 Aveanna Healthcare 的新股份，價值 43,000 美元。Oxford Asset Management LLP 在第二季度購買了 Aveanna Healthcare 的新股份，價值 64,000 美元。Bayesian Capital Management LP 在第二季度購買了 Aveanna Healthcare 的新股份，價值 85,000 美元。Jain Global LLC 在第四季度購買了 Aveanna Healthcare 的新股份，價值 102,000 美元。最後，Invesco Ltd.在第二季度將其在 Aveanna Healthcare 的持股增加了 31.1%。Invesco Ltd.現在擁有 20,006 股公司股票，價值 105,000 美元，此前在上個季度又購買了 4,742 股。87.96% 的股票由機構投資者持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新的目標價</h2>
</div><p>AVAH has been the subject of a number of recent research reports. Raymond James Financial upgraded Aveanna Healthcare from an &#34;outperform&#34; rating to a &#34;strong-buy&#34; rating and set a $13.00 target price for the company in a report on Friday, March 20th. Truist Financial dropped their target price on Aveanna Healthcare from $9.00 to $8.00 and set a &#34;hold&#34; rating for the company in a report on Monday, April 13th. Zacks Research cut Aveanna Healthcare from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, February 3rd. BMO Capital Markets dropped their target price on Aveanna Healthcare from $11.00 to $10.00 and set an &#34;outperform&#34; rating for the company in a report on Friday, March 20th. Finally, Barclays dropped their target price on Aveanna Healthcare from $11.00 to $9.50 and set an &#34;overweight&#34; rating for the company in a report on Wednesday, March 25th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $10.25.</p>
<div class="lb-trans"><p>AVAH 最近成為多份研究報告的主題。Raymond James Financial 將 Aveanna Healthcare 的評級從 “跑贏大盤” 上調至 “強力買入”，並在 3 月 20 日的報告中設定了 13.00 美元的目標價。Truist Financial 將 Aveanna Healthcare 的目標價從 9.00 美元下調至 8.00 美元，並在 4 月 13 日的報告中為該公司設定了 “持有” 評級。Zacks Research 在 2 月 3 日的報告中將 Aveanna Healthcare 的評級從 “強力買入” 下調至 “持有”。BMO Capital Markets 在 3 月 20 日的報告中將 Aveanna Healthcare 的目標價從 11.00 美元下調至 10.00 美元，併為該公司設定了 “跑贏大盤” 評級。最後，Barclays 在 3 月 25 日的報告中將 Aveanna Healthcare 的目標價從 11.00 美元下調至 9.50 美元，併為該公司設定了 “增持” 評級。一位投資分析師對該股票給予了強力買入評級，四位給予了買入評級，六位給予了持有評級。根據 MarketBeat，該股票目前的共識評級為 “適度買入”，共識目標價為 10.25 美元。</p>
</div><p><strong>View Our Latest Report on AVAH</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 AVAH 的最新報告</strong></p>
</div><h2>About Aveanna Healthcare</h2>
<div class="lb-trans"><h2>關於 Aveanna Healthcare</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Aveanna Healthcare, Inc NASDAQ: AVAH is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna's offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.</p>
<div class="lb-trans"><p>Aveanna Healthcare, Inc NASDAQ: AVAH 是一家全國性的居家醫療服務提供商，專注於為醫學複雜和慢性病兒童提供兒科專業護理、治療及相關支持。該公司提供一系列臨牀和治療解決方案，旨在使患者能夠在自己舒適的家中接受護理，從而減少住院和長期機構護理的需求。Aveanna 的服務包括註冊護士、物理治療、職業治療、語言治療、行為健康諮詢以及耐用醫療設備協調。</p>
</div><p>In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.</p>
<div class="lb-trans"><p>除了兒科居家健康服務外，Aveanna 還運營成人居家健康和個人護理支持項目，幫助老年人和殘疾成年人進行日常生活活動、藥物管理和康復治療。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Aveanna Healthcare</li>
<li>YETI Rallies After Earnings Beat and Raised Outlook</li>
<li>How the 3 Leading Quantum Firms Stack Up After Q1 Earnings</li>
<li>Cisco’s Vertical Rally May Still Be in the Early Innings</li>
<li>Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比 Aveanna Healthcare 更好的股票</li>
<li>YETI 在財報超預期和上調前景後反彈</li>
<li>三家領先量子公司的 Q1 財報對比</li>
<li>思科的垂直反彈可能仍處於早期階段</li>
<li>亞馬遜與阿里巴巴：現在顯然更具價值的選擇</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVZBSA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=AVAH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Aveanna Healthcare Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Aveanna Healthcare 嗎？</h2>
</div><p>Before you consider Aveanna Healthcare, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Aveanna Healthcare 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aveanna Healthcare wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Aveanna Healthcare 並不在名單上。</p>
</div><p>While Aveanna Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管 Aveanna Healthcare 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Aveanna Healthcare (NASDAQ:AVAH) Releases Earnings Results, Beats Estimates By $0.05 EPS

Market Beat

Aveanna Healthcare

Aveanna Healthcare (NASDAQ:AVAH) 公佈了財報，每股收益超出預期 0.05 美元